A Phase I Clinical Study of High Dose Ketoconazole Plus Weekly Docetaxel for Metastatic Castration Resistant Prostate Cancer

Journal of Urology

Volumn 183, Issue 6, 2010, Pages 2219-2226

  Figg, William D ^a   Woo, Sukyung ^a   Zhu, Wenhui ^a   Chen, Xiaohong ^a   Ajiboye, A Seun ^a   Steinberg, Seth M ^a   Price, Douglas K ^a   Wright, John J ^a   Parnes, Howard L ^a   Arlen, Philip M ^a   Gulley, James L ^a   Dahut, William L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

docetaxel; drug interactions; ketoconazole; prostatic neoplasms

Indexed keywords

DEXAMETHASONE; DOCETAXEL; HYDROCORTISONE; KETOCONAZOLE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BEDTIME DOSAGE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; GENOTYPE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; INFECTION; LEUKOPENIA; LIVER FUNCTION TEST; LIVER TOXICITY; LYMPHOCYTOPENIA; MALE; MELENA; METASTASIS POTENTIAL; MONOTHERAPY; MORNING DOSAGE; MUSCLE WEAKNESS; NAIL; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SENSORY NEUROPATHY; SIDE EFFECT; SOFT TISSUE DISEASE; TASTE; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; KETOCONAZOLE; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT FAILURE;

EID: 77951877997     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.02.020     Document Type: Article

References (25)

1. Smith B.D., Smith G.L., Hurria A., et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27 (2009) 2758
2. Damber J.E., and Aus G. Prostate cancer. Lancet 371 (2008) 1710
3. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502
4. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513
5. Petrylak D.P. Future directions in the treatment of androgen-independent prostate cancer. Urology 65 (2005) 8
6. Blagosklonny M.V., Dixon S.C., and Figg W.D. Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines. J Urol 163 (2000) 1022
7. Sella A., Kilbourn R., Amato R., et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 12 (1994) 683
8. Engels F.K., Ten Tije A.J., Baker S.D., et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 75 (2004) 448
9. Van Veldhuizen P.J., Reed G., Aggarwal A., et al. Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study. Cancer 98 (2003) 1855
10. Halabi S., Small E.J., Kantoff P.W., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21 (2003) 1232
11. Huang Y.C., Colaizzi J.L., Bierman R.H., et al. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob Agents Chemother 30 (1986) 206
12. Daneshmend T.K., Warnock D.W., Turner A., et al. Pharmacokinetics of ketoconazole in normal subjects. J Antimicrob Chemother 8 (1981) 299
13. Figg W.D., Liu Y., Arlen P., et al. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol 173 (2005) 790
14. Marcelin-Jimenez G., Hernandez J., Angeles A.P., et al. Bioequivalence evaluation of two brands of ketoconazole tablets (Onofin-K and Nizoral) in a healthy female Mexican population. Biopharm Drug Dispos 25 (2004) 203
15. Trump D.L., Havlin K.H., Messing E.M., et al. High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. J Clin Oncol 7 (1989) 1093
16. Johnson D.E., Babaian R.J., von Eschenbach A.C., et al. Ketoconazole therapy for hormonally refractive metastatic prostate cancer. Urology 31 (1988) 132
17. Vanuytsel L., Ang K.K., Vantongelen K., et al. Ketoconazole therapy for advanced prostatic cancer: feasibility and treatment results. J Urol 137 (1987) 905
18. Oh W.K. Secondary hormonal therapies in the treatment of prostate cancer. Urology 60 (2002) 87
19. Eklund J., Kozloff M., Vlamakis J., et al. Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer. Cancer 106 (2006) 2459
20. Wire M.B., Ballow C.H., Borland J., et al. Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged. Antimicrob Agents Chemother 51 (2007) 2982
21. Small E.J., Halabi S., Dawson N.A., et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22 (2004) 1025
22. Berthold D.R., Pond G.R., Soban F., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26 (2008) 242
23. Sissung T.M., Baum C.E., Deeken J., et al. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res 14 (2008) 4543
24. Lepper E.R., Baker S.D., Permenter M., et al. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res 11 (2005) 7398
25. Hamada A., Sissung T., Price D.K., et al. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 14 (2008) 3312